Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
Use of romiplostim in the ITP treatment pathway, compared with eltrombopag or SoC, is likely to be cost effective in Ireland. Romiplostim improves clinical outcomes by increasing platelet counts, reducing bleeding events and the use of IVIg and steroids, resulting in both cost savings and additional QALYs when compared with current treatment practices. </AbstractSection> Copyright The Author(s) 2013
Year of publication: |
2013
|
---|---|
Authors: | Lee, Dawn ; Thornton, Patrick ; Hirst, Alexander ; Kutikova, Lucie ; Deuson, Robert ; Brereton, Nic |
Published in: |
Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 11.2013, 5, p. 457-469
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Lee, Dawn, (2013)
-
Hirst, Alexander, (2016)
-
Meng, Yang, (2018)
- More ...